Common data elements for clinical research in Friedreich's ataxia
暂无分享,去创建一个
K. Fischbeck | P. Kaufmann | S. Perlman | M. Pandolfo | S. Raman | M. Delatycki | D. Lynch | J. Odenkirchen | J. Schulz | R. M. Payne | R. Shaddy | J. Farmer | P. Kantor | L. Hunegs | K. Miller | R. Payne | Petra Kaufmann
[1] A. Duhaime,et al. Common data elements for research on traumatic brain injury: pediatric considerations. , 2012, Journal of neurotrauma.
[2] Rachel P Berger,et al. Common data elements for pediatric traumatic brain injury: recommendations from the working group on demographics and clinical assessment. , 2012, Journal of neurotrauma.
[3] S. Heald,et al. Use of an Adaptive Study Design in Single Ascending‐Dose Pharmacokinetics of A0001 (α‐Tocopherylquinone) in Healthy Male Subjects , 2012, Journal of clinical pharmacology.
[4] N. Barbaro,et al. Common data elements in epilepsy research: Development and implementation of the NINDS epilepsy CDE project , 2011, Epilepsia.
[5] Henry L. Lew,et al. Common data elements for traumatic brain injury: recommendations from the interagency working group on demographics and clinical assessment. , 2010, Archives of physical medicine and rehabilitation.
[6] S. Perlman,et al. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. , 2010, Archives of neurology.
[7] S. Hecht,et al. Does oxidative stress contribute to the pathology of Friedreich's ataxia? A radical question , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] A. Blamire,et al. Analysis of the factors influencing the cardiac phenotype in Friedreich's ataxia , 2010, Movement disorders : official journal of the Movement Disorder Society.
[9] D. Lynch,et al. Health-related quality of life in children with Friedreich ataxia. , 2010, Pediatric neurology.
[10] M. Pandolfo,et al. PGC-1alpha Down-Regulation Affects the Antioxidant Response in Friedreich's Ataxia , 2010, PloS one.
[11] K. Bushara,et al. Measuring the rate of progression in Friedreich ataxia: Implications for clinical trial design , 2010, Movement disorders : official journal of the Movement Disorder Society.
[12] Dagmar Timmann,et al. Comparison of three clinical rating scales in Friedreich ataxia (FRDA) , 2009, Movement disorders : official journal of the Movement Disorder Society.
[13] D. Geschwind,et al. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARγ pathway as a therapeutic target in Friedreich’s ataxia , 2009, Human molecular genetics.
[14] K. Fischbeck,et al. Clinical experience with high-dose idebenone in Friedreich ataxia , 2009, Journal of Neurology.
[15] Robert B. Wilson,et al. Pharmacotherapy for Friedreich Ataxia , 2009, CNS drugs.
[16] T. Ashizawa,et al. Health related quality of life measures in Friedreich Ataxia , 2008, Journal of the Neurological Sciences.
[17] W. Poewe,et al. Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin , 2007, Annals of neurology.
[18] K. Fischbeck,et al. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial , 2007, The Lancet Neurology.
[19] L. Corben,et al. Quality of life in Friedreich ataxia: what clinical, social and demographic factors are important? , 2007, European journal of neurology.
[20] P. Bauer,et al. Cardiomyopathy in Friedreich's ataxia‐assessment by cardiac MRI , 2007, Movement disorders : official journal of the Movement Disorder Society.
[21] Nathalie Boddaert,et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. , 2007, Blood.
[22] S. Perlman,et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia , 2006, Nature chemical biology.
[23] J. Hobart,et al. International cooperative ataxia rating scale (ICARS): Appropriate for studies of Friedreich's ataxia? , 2005, Movement disorders : official journal of the Movement Disorder Society.
[24] L. Balcer,et al. Performance measures in Friedreich ataxia: Potential utility as clinical outcome tools , 2005, Movement disorders : official journal of the Movement Disorder Society.
[25] L. Balcer,et al. Contrast Letter Acuity as a Measure of Visual Dysfunction in Patients with Friedreich Ataxia , 2002, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.
[26] L. Balcer,et al. Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. , 2002, Archives of neurology.
[27] A. Munnich,et al. Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia , 1997, Nature Genetics.
[28] M. Pandolfo,et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. , 1997, Science.
[29] I. G. Fantus,et al. Evidence for abnormal regulation of insulin receptors in Friedreich's ataxia. , 1993, The Journal of clinical endocrinology and metabolism.
[30] G. Finocchiaro,et al. Glucose metabolism alterations in Friedreich's ataxia , 1988, Neurology.
[31] I. G. Fantus,et al. Glucose intolerance in Friedreich's ataxia: association with insulin resistance and decreased insulin binding. , 1986, Metabolism: clinical and experimental.
[32] A. Harding. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. , 1981, Brain : a journal of neurology.